test

Steve R. Bailey

@Frazier Life Sciences Management, L.p.

Latest period2024 - Q3ReportedManaged Assets$2.495BTotal holdings53
Assets growth rate16.72%Assets growth rate (2-Q avg)3.46%Continuous growth in asset value1 quarters

Portfolio positions

This chart displays the top 10 holdings in Frazier Life Sciences Management, L.p.'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 53 positions.

Assets under management

The assets under management (AUM) of Frazier Life Sciences Management, L.p. over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 2.495B in assets, with a quarterly growth rate of 16.72% and a 2-quarter average growth rate of 3.46%. The portfolio is managed by Steve R. Bailey, and others.

Portfolio holdings

CurrentNew PositionIncreasedDecreasedExited
InvestmentPortfolio %Reported Value
TYRATyra Biosciences Inc
Recent Activity
Decreased -12.16%
0.69%
$17.186M
731,020 shares@ $23.51 avg price
AUTLAutolus Therapeutics Plc
Recent Activity
0.68%
$16.783M
4.623M shares@ $3.63 avg price
ALKSAlkermes Plc
Recent Activity
New Position
0.65%
$16.126M
576,129 shares@ $28.0 avg price
IMTXImmatics N.v
Recent Activity
Increased 17.55%
0.62%
$15.457M
1.355M shares@ $11.42 avg price
ORKAOruka Therapeutics Inc
Recent Activity
New Position
0.47%
$11.699M
477,327 shares@ $24.52 avg price
LXEOLexeo Therapeutics Inc
Recent Activity
New Position
0.46%
$11.307M
1.251M shares@ $9.04 avg price
DSGNDesign Therapeutics Inc
Recent Activity
Increased 58.35%
0.41%
$10.182M
1.893M shares@ $5.39 avg price
COGTCogent Biosciences Inc
Recent Activity
0.41%
$10.115M
936,576 shares@ $10.81 avg price
MGNXMacrogenics Inc
Recent Activity
0.4%
$9.905M
3.011M shares@ $3.3 avg price
DAWNDay One Biopharmaceuticals I
Recent Activity
New Position
0.39%
$9.607M
689,655 shares@ $13.93 avg price